Stem Cell Banking: The Perspective of an iPS Donor Family

“Your twin daughters have an extremely rare, fatal disease called Niemann Pick Type C and there’s nothing you can do for them”. Those were the devastating words that Chris Hempel and her husband first heard in 2007. Rather than just give in to this fate, the Hempels are proactively engaging researchers to try to save Addi and Cassi’s lives. This journey includes donating skin samples to cell banks so that researchers can create induced pluripotent stem (iPS) cells, a promising technology which may help undercover treatments for their daughters. In this video, Chris Hempel speaks to the CIRM Standards Working Group to present a patient advocate’s perspective on the challenges of rare disease research. Hempel was introduced by CIRM Governing Board member, Sherry Lansing.

For more information about the Hempels and Niemann Pick Type C, visit: http://addiandcassi.com/

Successful stem cell therapy for COPD

For more information see this additional video, Lung Disease and COPD

Cardiovascular Therapies: Spotlight on Stem Cell Research

“Welcoming Remarks” (Part 1 of a 4-part series)

Robert Klein, J.D. and Claire Pomeroy, M.D., M.B.A., gave the welcoming remarks for the “Spotlight on Cardiovascular Therapies,” an educational event presented at the California Institute for Regenerative Medicine Governing Board meeting on March 10, 2011 in Burlingame, CA.

Klein is Chair of the CIRM Governing Board. Pomeroy is Vice Chancellor for Human Health Sciences at UC Davis and Dean of the UC Davis School of Medicine.

The entire series can be found at http://www.youtube.com/user/CIRMTV

The California Institute for Regenerative Medicine, the state stem cell agency, funds adult and embryonic stem cell research at institutions and for-profit organizations in California. These funds are accelerating a field of research that holds the possibility of bringing new therapies for debilitating diseases.

Adult Stem Cells for Treatment of Rheumatoid Arthritis

Dr. Thomas Ichim and Dr. Bob Harman discuss use of fat stem cells for treatment of rheumatoid arthritis. These two recently published a paper on this as part of a Medistem/Vet-Stem collaboration.

About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. For more informarion visit website: http://www.medisteminc.com/

About Vet-Stem
Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine technology to the veterinary profession. Our goal is to be the conduit for the latest developments in human medical technology and provide easy-to-use services and products to the practicing veterinarian. For more information visit website: http://www.vet-stem.com/

Stem Cells: the Hope, the Hype and the Science

UCSF’s Osher Center for Integrative Medicine presents Stem Cells and Regenerative Medicine: The science behind emerging treatment advances and personalized medicine.

Stem cells from body fat promising

A San Diego-based company is breaking new ground in the field of regenerative medicine with a system that uses patients’ own body fat to generate stem cells and repair tissue and organs. Ben Gruber reports.

Stem Cells Could Regrow Joints

Arthritis patients might soon be able to replace their failing joints with joints grown from their own stem cells, rather than conventional artificial replacements. A proof of concept experiment first reported by ”The Lancet” showed that rabbits were able to regenerate their own joints and researchers say they now want to start clinical trials with humans. Tara Cleary reports.

Does our DNA determine how well we respond to stem-cell transplantations?

SEATTLE — Jan. 19, 2011 — Do genetic variations in DNA determine the outcome and success in patients who undergo stem-cell transplantation to treat blood cancers and predict complications? The National Heart, Blood and Lung Institute of the National Institutes of Health has awarded a $4.3 million, four-year grant to Fred Hutchinson Cancer Research Center to help find out.

John Hansen, M.D., a member of the Hutchinson Center’s Clinical Research Division and medical director of Clinical Immunogenetics at Seattle Cancer Care Alliance, will lead the genome-wide association study of all patients who have been treated with an allogeneic hematopoietic cell transplant (HCT) at the Hutchinson Center between 1992 and 2010. Allogeneic stem-cell transplants involve infusing healthy stem cells from the blood or bone marrow of related and unrelated donors into the blood of patients whose blood-cell-producing bone marrow is diseased by leukemia and lymphoma, among other illnesses.

The new study will expand upon earlier research begun in 2006 and will increase the sample size three fold to 5,000 transplants, thus improving the power of identifying the genetic variants associated with HCT outcome.

Among the study’s goals are to identify genetic variations among patients that could account for the risk and severity of acute and chronic graft-versus-host disease, organ toxicity, opportunistic infection, relapse and overall survival. Genetic variants associated with HCT outcome will be validated as markers for assessing risk prior to patients receiving transplants and to enhance counseling and treatment planning.

Researchers also will use the results to gain insights into disease processes responsible for treatment complications and the rationale for developing novel targeted therapies for preventing and controlling these complications.

Bone-marrow and stem-cell transplantation was developed at the Hutchinson Center as highly successful treatments for blood cancers and some autoimmune diseases. Researchers at the Hutchinson Center and its clinical partner, SCCA, have performed more transplants cumulatively over the years than any other center in the world. In 2010, about 60,000 people worldwide underwent bone- or stem-cell transplants, and by the end of 2011 it is expected that about 1 million people worldwide will have been treated by this life-saving therapy, which was pioneered by the Hutchinson Center’s E. Donnall Thomas, M.D., who in 1990 received the Nobel Prize in physiology or medicine for this advance.

Man Cured Of HIV By Stem Cell Treatment

Stem cell treatment for peripheral artery disease

Stem cells taken from placentas are helping people walk again without pain.

HealthFirst reporter Leslie Toldo shows us how this experimental therapy may help millions of people.

Click link for complete article.